# Treatment options for chronic hepatitis B
The treatment of chronic hepatitis B aims to suppress viral replication, reduce inflammation in the liver and thus prevent liver disease, cirrhosis and liver cancer. The choice for treatment and the type of medication depend on factors such as the viral status (HBeAg status), the extent of liver damage (fibrosis grade) and the activity of liver enzymes. Treatment is not always immediately necessary; sometimes a wait-and-see approach (watchful waiting) is adopted first.
Nucleos(t)ide analogues
These are medications that prevent the virus from replicating itself. They form the cornerstone of treatment for most patients with chronic hepatitis B.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Nucleos(t)ide analogues work by interfering with the reverse transcriptase of the hepatitis B virus. This is the enzyme the virus needs to copy its genetic material. By blocking this enzyme, the virus can multiply much less effectively.
These medications are taken long-term (often for years or for life). They can suppress the virus very effectively; many patients achieve and maintain an undetectable viral load with them.
Known side effects are generally mild. Some preparations may affect kidney function or bone density with long-term use. Liver function must be checked regularly. Very rarely, these medications, if stopped abruptly without guidance, can cause a so-called 'flare' (acute worsening of the disease).
In some patients, resistance to the medication can develop after years of use — the virus mutates and no longer responds to the drug. This usually requires switching to a different preparation.
Recent studies are investigating whether certain markers (HBsAg isoforms, viral load or HBcrAg levels) can help predict which patients can better stop after years of treatment with nucleos(t)ide analogues, but this is not yet standard in clinical practice.
Interferons
These are the body's own immune substances that activate the immune system to fight the virus.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Pegylated interferon alfa (peg-IFNα) is a modified form of natural interferon. It stimulates the patient's own immune cells to attack the virus. This medication is injected (usually weekly), not taken as a daily tablet.
Pegylated interferon alfa is often used in combination with nucleos(t)ide analogues in patients with HBeAg-positive disease (i.e. the patient carries the e-antigen of the virus) and mild to moderate liver fibrosis. The goal is often to permanently eliminate the virus (at least in part), so that medications can be stopped later.
Side effects of interferons are well-known and can be substantial. Many users experience flu-like symptoms (fever, muscle pain, fatigue), especially in the days after injection. Psychological side effects such as depression or irritability sometimes occur. Interferons can also affect inflammation markers and certain blood values. This is why its use is carefully considered and regularly monitored.
A specific risk is that interferon treatment, especially in patients with certain antibodies against cellular proteins (anti-Ro52), can increase the risk of autoimmune diseases. This is something doctors are alert to.
Bepirovirsen
This is a new type of medication that works differently from classical antiviral drugs.
ResearchediPositive results in clinical studies, not yet standard treatment
Bepirovirsen is a so-called antisense oligonucleotide. It hampers the production of hepatitis B proteins by attaching itself to the viral genetic material and thus disrupting the virus's reading process. This medication also stimulates the patient's immune system to better attack the virus itself.
Recent research shows that bepirovirsen is capable of activating innate immune proteins, independent of viral load. This suggests a potential advantage over purely antiviral agents.
The side effect profile is still under investigation; toxicity with use has been acceptable so far in clinical studies.
Other experimental approaches
Research into new vaccines and immunomodulatory strategies is ongoing.
ExperimentaliOngoing in study setting, outcome still unknown
J-51 is an experimental lentiviral vector vaccine being tested in pilot studies. It aims to "retrain" the immune system of patients with chronic hepatitis B so that the virus is better recognized and combated. Initial safety data are encouraging, but evidence of efficacy is still limited.
Other approaches being investigated consist of combinations of existing agents, modifications of interferon schedules (for example with nucleos(t)ide analogues), and research into traditional medicine (such as certain herbal therapies), although the latter are not yet sufficiently established for regular clinical practice.
Monitoring and supportive care
Regardless of which specific treatment is chosen, regular monitoring is essential.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Patients undergoing treatment undergo regular blood tests (liver function, viral load, certain antibodies) and sometimes imaging (ultrasound or elastography of the liver) to determine whether the disease is under control, whether the virus is decreasing, and how the liver structure is developing.
Point-of-care ultrasound equipment is used in some regions to enable rapid on-site liver assessments, particularly in clinics serving many patients.
In patients with coinfection (hepatitis B and hepatitis C, or hepatitis B and HIV), treatment schedules must be carefully coordinated, since certain drug combinations work better than others.
Lifestyle modifications — limiting alcohol use, healthy diet, normal weight — support medication efficacy and slow further liver damage.
Treatment during pregnancy
For pregnant women with chronic hepatitis B, special policies apply.
ProveniIncluded in official guidelines, or approved by EMA or FDA
During pregnancy, certain nucleos(t)ide analogues can be safely continued or even started to prevent transmission to the child. The choice depends on the trimester and the level of viral load. Interferons are avoided in pregnancy due to risks to the fetus.
After delivery, babies of infected mothers remain protected by vaccination and passive antibodies (immunoglobulin); appropriate neonatal care is crucial.
Special scenarios: resistance and switch therapy
If a virus becomes resistant to one nucleos(t)ide analogue, the medication must be switched.
ProveniIncluded in official guidelines, or approved by EMA or FDA
This occurs to another nucleos(t)ide analogue to which the virus is (still) susceptible, or to a combination. Recent guidelines and research are investigating which switches are most effective based on the individual viral genome and previous treatment history. This requires assessment by specialists.
Interruption of long-term treatment is considered only under strict medical supervision. Whether and when this is possible depends on markers such as HBsAg levels and viral load after years of therapy; not all factors predicting success are yet clear.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._